Vendor Intelligence Report: PurePeptides

Published 13 Jun 2026. 32-page investigative report on who is behind PurePeptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 16 Finnrick lab tests, PurePeptides recorded 11 pass / 5 fail — an overall pass rate of 69%. The record is sharply product-specific: Tirzepatide is the strongest tested item, Retatrutide is usable but less clean, and Ipamorelin is the clear problem case with repeated failures. The full report shows how scores move under stricter grading, especially when fill accuracy is tightened.

The operating trail is more traceable than many gray-market storefronts, but not especially transparent. The Terms name Elite Health LLC, and Wisconsin/Florida filings tie that entity to a small health-services footprint; the checkout-facing site does not present named operators or a physical address. An archived Terms capture also retains Limitless Life Nootropics hyperlinks, showing copied or inherited legal text without proving shared ownership or supply.

Product and regulatory signals diverge. PurePeptides publishes third-party MZ Biolabs documentation for at least one BPC-157 lot, but that same document raises a quantity-control question while the endotoxin report is favorable. Its GLP-RT and GLP-TZ products sit in a high regulatory-continuity-risk category: peer FDA letters have targeted Retatrutide and Tirzepatide sold under similar GLP-style names, even though no public FDA warning letter naming PurePeptides was found as of the report date.

Reputation evidence is thin but not empty. Trustpilot no longer displays the profile, and the promotion scan found an X/Reddit discount-code network where referral disclosure is weak. The buyer takeaway is directional: PurePeptides looks most defensible for tested Tirzepatide, less clean for Retatrutide, and hard to justify for Ipamorelin without current independent lot testing.

Inside the full report:

  • Per-product Finnrick pass/fail rates, rating trajectories, and methodology-divergence charts for all 3 tested products
  • Corporate filings and name-history records for Elite Health LLC across Wisconsin and Florida
  • Archived Terms & Conditions evidence showing Limitless Life Nootropics hyperlink lineage
  • GLP-RT sequence capture and FDA warning-letter comparison for GLP-RT/GLP-TZ
  • MZ Biolabs BPC-157 COA/endotoxin documents and quantity-control analysis
  • Affiliate-promotion scan covering X posts, Reddit code evidence, coupon paths, and Trustpilot removal

Risk assessment

  • Ipamorelin quality-control risk — high: Ipamorelin failed 4 of 4 Finnrick tests and carries a 54.48% Finnrick rating; Tirzepatide and Retatrutide tested materially stronger.
  • GLP-RT / GLP-TZ regulatory-continuity risk — high: GLP-RT and GLP-TZ are Retatrutide/Tirzepatide analogs sold under GLP naming; FDA warning letters to peers target similar RUO GLP sales and obfuscated names.
  • Undisclosed affiliate-promotion risk — medium: The scan found 9 referral-code/link promoters and 0 clear disclosures among them, including RB10, DRM10, JB10, MITOCHONDRIA, DNA10, and TDog10.
  • Legal-documentation / Limitless-affiliation risk — medium: PurePeptides Terms were copied from Limitless Life Nootropics with hrefs pointing to limitlesslifenootropics.com; the business relationship is unexplained.
  • Operator-transparency risk — medium: The site does not disclose a physical address or named operators; public filings identify Elite Health LLC and Gwen Sweeney.
  • Review-platform / reputation risk — medium: Trustpilot says the purepeptides.bio profile goes against guidelines and is no longer visible; the reason is not stated.